ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer

• Main Authors: Fangqi Ma (Author), Mingming Ren (Author), Zhongqiu Li (Author), Yujing Tang (Author), Xiaoyu Sun (Author), Yi Wang (Author), Nida Cao (Author), Xiaohong Zhu (Author), Yan Xu (Author), Rui Wang (Author), Yumiao Shen (Author), Ruohan Zhao (Author), Zhaoyan Li (Author), Milad Ashrafizadeh (Author), Gautam Sethi (Author), Furong Wang (Author), Aiguang Zhao (Author)
• Format: Book
• Published: Elsevier, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ARID1A deletion mutation contributes to improved treatment of several malignancies with immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Here, we report an increase of CD8+ T cells infiltration in GC...